Stay updated with breaking news from Immunization Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.
NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Tuesday positive top-line data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus or RSV